Skip to main content
Figure 2 | BMC Medicine

Figure 2

From: Bridging the clinical gaps: genetic, epigenetic and transcriptomic biomarkers for the early detection of lung cancer in the post-National Lung Screening Trial era

Figure 2

Biological rationale for addressing clinical issues by using upstream early events that ultimately lead to lung cancer phenotypes as genomic biomarkers. The diagram highlights early upstream markers for diagnosing or screening of lung cancer far in advance of the development of clinically evident invasive carcinomas, which are mainly driven by genetic, epigenetic and transcriptomic damage.

Back to article page